Entegris (ENTG) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
17 Jan, 2026Executive summary
Q3 2024 net sales were $807.7M–$808M, down 9% year-over-year due to divestitures, but adjusted sales (excluding divestitures) rose 7% year-over-year.
GAAP net income rose to $77.6M, with diluted EPS at $0.51 and non-GAAP EPS at $0.77, both within guidance.
Gross margin improved to 46.0% (GAAP and non-GAAP), up from 41.3% a year ago.
Segment realignment announced, combining MC and AMH divisions to drive $10–$15M in annualized cost savings and enhance operational capabilities.
The company completed the sale of its PIM business for $256.2M net proceeds and continues to invest in new facilities in Taiwan and Colorado.
Financial highlights
Q3 2024 sales were $807.7M–$808M, up 7% year-over-year excluding divestitures, but down 9% as reported and down 1% sequentially.
Gross margin was 46.0%; adjusted EBITDA margin was 28.8%; adjusted operating margin was 23.0%.
GAAP diluted EPS was $0.51; non-GAAP EPS was $0.77; adjusted net income was $117.6M.
Free cash flow was $115M; CapEx was $82M; cash and equivalents at quarter-end were $432M.
Net income margin for Q3 2024 was 9.6% (GAAP).
Outlook and guidance
Q4 2024 sales expected between $810M–$840M, with ~8% year-over-year growth excluding divestitures.
Q4 EBITDA margin expected at 28.5%–29.5%; GAAP EPS $0.49–$0.56; non-GAAP EPS $0.75–$0.82.
Full-year 2024 sales expected to grow 4% and EBITDA 8% (excluding divestitures); management expects cash and cash flow to meet business needs.
Industry growth for 2024 revised to 1–2%, with company outperformance of about three points expected.
No material impact expected from global minimum tax legislation; ongoing monitoring of global risks.
Latest events from Entegris
- Annual meeting to vote on directors, compensation, auditor, and key shareholder rights changes.ENTG
Proxy filing23 Mar 2026 - Proxy covers leadership transition, governance reforms, and performance-based compensation changes.ENTG
Proxy filing23 Mar 2026 - Strategic growth, governance reforms, and enhanced ESG drive long-term value creation.ENTG
Proxy Filing6 Mar 2026 - Q4 2025 delivered strong sales and margins, with robust 2026 guidance and ongoing deleveraging.ENTG
Q4 202510 Feb 2026 - Q2 sales rose sequentially with strong margins; Q3 guidance and investments support further growth.ENTG
Q2 20242 Feb 2026 - Q4 2024 delivered double-digit adjusted sales growth and margin expansion, beating guidance.ENTG
Q4 20248 Jan 2026 - Q2 2025 sales were $792.4M, with Q3 non-GAAP EPS guided at $0.68–$0.75.ENTG
Q2 202517 Dec 2025 - Strong 2024 growth, robust governance, and key votes on directors, pay, auditor, and voting rights.ENTG
Proxy Filing1 Dec 2025 - Q1 2025 net sales rose 5% adjusted, with margin gains and tariff risks impacting outlook.ENTG
Q1 202517 Nov 2025